B
ENGN icon

Braidwell’s enGene Therapeutics ENGN Stock Holding History

Braidwell’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,456,870
Closed -$16.7M – 96
2026
Q1 		$16.7M Sell
2,456,870
-674,449
-22% -$6M 0.56% 60
2025
Q4 		$28.3M Buy
3,131,319
+865,000
+38% +$6.93M 0.9% 43
2025
Q3 		$15.5M Buy
+2,266,319
New +$10.3M 0.46% 53

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Braidwell's ENGN Position: Q2 2026 in Review

Braidwell sold out of enGene Therapeutics (ENGN) in Q2 2026, closing a stake of 2,456,870 shares — an estimated $16.7M sold.

Braidwell first reported a position in ENGN in Q3 2025 and held it in 3 quarters. The position peaked at $28.3M in Q4 2025. 60 funds tracked by Wall St. Rank hold ENGN as of Q2 2026.

  • Braidwell reported no remaining enGene Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Braidwell sold 2,456,870 enGene Therapeutics shares in Q2 2026, an estimated $16.7M.
  • Braidwell first reported a position in enGene Therapeutics in Q3 2025 and held it in 3 quarters.
  • Braidwell's enGene Therapeutics position peaked at $28.3M in Q4 2025.
  • 60 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2026.

Based on Braidwell's 13F filing for Q2 2026, filed 14 Aug 2026.